High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion

Kim, Ha-Jeong; Jeon, Hye-Kyung; Cho, Young Jae; Park, Young Ae; Choi, Jung-Joo; Do, In‐Gu; Song, Suk-Won; Lee, Yoo-Young; Choi, Chel Hun; Kim, Tae-Joong; Bae, Duk-Soo; Lee, Jeong‐Won; Kim, Byoung-Gie

doi:10.1016/j.ejca.2012.02.005

Cited by 71 publications

(74 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given their role in apoptosis, it is not surprising that galectins play a central role in the control of cell proliferation in tumors. This has been well documented in the case of galectin-1, which reduces proliferation of B-cell lymphomas, neuroblastoma and LnCap prostate cancer cells while it increases cell division of glioma, cervical, ovarian and pancreatic cancer cells (12,51,58,61,62,64,93). A similar case exists for galectin-3, which displays, once more dual functionalities in cell proliferation.…”

Section: Galectin (%) Cellular --------------------------------------mentioning

confidence: 83%

“…For instance, galectin-1 increases adhesion of colorectal and prostate cancer cells (59,108) and stimulates migration of hepatic and lung cancer cells, while reducing colorectal cell migration (63,(109)(110)(111). It also increases the invasive behavior of gliomas, lung, ovarian, hepatic, pancreatic and cervical cancer cells (51,63,64,109,(111)(112)(113)(114)(115). The ability of galectins to increase adhesion and migration has been well documented in the case of galectin-2 and most notably in the case of galectin-3 (47,67,97,116-120).…”

Section: Galectin (%) Cellular --------------------------------------mentioning

confidence: 97%

“…A positive correlation between the expression of galectin-1 and -3 and malignant transformation has been established using different cellular models (49)(50)(51) (12,(58)(59)(60)(61). Conversely, it reduces apoptosis in gliomas, cervical and lung cancer (62)(63)(64). Galectin-3 has also been shown to modulate apoptosis.…”

Section: Intracellular Functions Of Galectins In Cancermentioning

confidence: 99%

See 2 more Smart Citations

Intracellular galectins in cancer cells: Potential new targets for therapy

Vladoiu

Labrie

St‐Pierre

2014

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Dysregulation of galectin expression is frequently observed in cancer tissues. Such an abnormal expression pattern often correlates with aggressiveness and relapse in many types of cancer. Because galectins have the ability to modulate functions that are important for cell survival, migration and metastasis, they also represent attractive targets for cancer therapy. This has been well-exploited for extracellular galectins, which bind glycoconjugates expressed on the surface of cancer cells. Although the existence of intracellular functions of galectins has been known for many years, an increasing number of studies indicate that these proteins can also alter tumor progression through their interaction with intracellular ligands. In fact, in some instances, the interactions of galectins with their intracellular ligands seem to occur independently of their carbohydrate recognition domain. Such findings call for a change in the basic assumptions, or paradigms, concerning the activity of galectins in cancer and may force us to revisit our strategies to develop galectin antagonists for the treatment of cancer.

show abstract

Section: Galectin (%) Cellular --------------------------------------mentioning

confidence: 83%

Section: Galectin (%) Cellular --------------------------------------mentioning

confidence: 97%

Section: Intracellular Functions Of Galectins In Cancermentioning

confidence: 99%

See 1 more Smart Citation

Intracellular galectins in cancer cells: Potential new targets for therapy

Vladoiu

Labrie

St‐Pierre

2014

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…24,25 This seems contradictory, however, in lung and ovarian cancer, gal-1 overexpression appears to promote chemotherapy resistance and downregulation of gal-1 expression can sensitize tumor cells to platin-based chemotherapy. 14,26,27 In ovarian cancer, gal-1 could possibly mediate these effects through activation of the H-Ras/Raf-1/ERK pathway. 14 The group of Le Mercier et al suggested that increased gal-1 levels therefore seem to be representative of defense mechanisms against cytotoxic drugs, such as chemotherapy, and that gal-1 could consequently be of major importance in chemotherapy resistance.…”

Section: Discussionmentioning

confidence: 99%

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course

et al. 2015

View full text Add to dashboard Cite

Neoplastic cells can escape immune control leading to cancer growth. Regulatory T cells (Treg), myeloidderived suppressor cells (MDSC) and tumor-associated macrophages (TAM) are crucial in immune escape. TAM are divided based on their immune profile, M1 are immunostimulatory while M2 are immunosuppressive. Research so far has mainly focused on the intratumoral behavior of these cells. This study, on the other hand, explored the systemic changes of the key metabolites [IL-4 (interleukin), IL-13, arginase, IL-10, VEGF-A (vascular endothelial growth factor), CCL-2 (chemokine (C-C) motif ligand 2) and TGF-b (transforming growth factor)] linked to Treg, MDSC and TAM during the course of the disease in ovarian and fallopian tube cancer patients. Serum samples were therefore analyzed at diagnosis, after (interval)-debulking surgery and after chemotherapy (paclitaxel-carboplatin). We also determined galectin-1 (gal-1), involved in angiogenesis and tumor-mediated immune evasion. We found significantly lower levels of IL-10, VEGF-A, TGF-b and arginase and higher levels of gal-1 after chemotherapy compared to diagnosis. After debulking surgery, a decrease in IL-10 was significant. Gal-1 and CCL-2 appeared independent prognostic factors for progression-free and overall survival (OS) (multivariate analysis). These results will help us in the decision making of future therapies in order to further modulate the immune system in a positive way.

show abstract

“…It is upregulated in human hepatocellular carcinoma (HCC), and is significantly associated with tumor invasive characteristics such as vascular invasion, suggesting it may be a new prognostic factor and a high-priority therapeutic target for HCC (16). Ovarian cancer patients with strong GAL1 peritumoral staining have poorer progression-free survival than patients with weak peritumoral staining, and inhibition of GAL1 results in the inhibition of cell growth and proliferation (17). OS is the most common malignant bone tumor in children and adolescents, unfortunately, with a poor clinical prognosis.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway

et al. 2014

View full text Add to dashboard Cite

Abstract. Galectin-1 (GAL1), a widely expressed β-galactoside-binding protein, exerts pleiotropic biological functions. GAL1 has been found to be upregulated in many malignancies; yet the role of GAL1 in the pathophysiology of human osteosarcoma (OS) remains uncertain. The present study was carried out to investigate the expression of GAL1 in human OS tissues and to explore its effects on the growth and invasion of OS cells. OS and corresponding adjacent non-cancerous tissues (ANCT) were collected from 30 consecutive cases. The expression of GAL1 was detected by immunohistochemical assay through tissue microarray procedure. Using small hairpin RNA (shRNA)-mediated GAL1 knockdown (Lv-shGAL1) in OS (MG-63 and U-2 OS) cells, we observed the changes in the malignant phenotype in OS cells in vitro and in vivo. As a consequence, the positive expression of GAL1 was significantly higher in OS tissues than that in the ANCT (63.3 vs. 36.7%, P=0.029), and was positively correlated with distant metastasis in the OS patients (P=0.022). Knockdown of GAL1 suppressed cell proliferative activities and invasive potential and induced apoptosis in OS cells with decreased expression of p38MAPK, p-ERK, Ki-67 and matrix metallopeptidase-9 (MMP-9) and increased expression of caspase-3. In addition, the tumor volume in the MG-63 subcutaneous tumor models treated with Lv-shGAL1 was significantly smaller than that in the negative control (NC) group (P<0.01). Altogether, our findings indicate that high expression of GAL1 is associated with distant metastasis of OS patients, and knockdown of GAL1 inhibits growth and invasion of OS cells possibly through inhibition of the MAPK/ERK pathway, suggesting that GAL1 may represent a potential target for the treatment of cancer.

show abstract

High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion

Cited by 71 publications

References 41 publications

Intracellular galectins in cancer cells: Potential new targets for therapy

Intracellular galectins in cancer cells: Potential new targets for therapy

Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course

Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway

Contact Info

Product

Resources

About